Tehran University of Medical Sciences Acta Medica Iranica 0044-6025 58 1 2020 06 16 47 49 Parvaneh Dehghan Department of Radiology, School of Paramedical Sciences, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran. AND Health Sciences Research Center, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran. Samaneh Kakhki Health Sciences Research Center, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran. AND Department of Nursing, School of Nursing and Midwifery, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran. 2019 07 20 2020 04 23 Intrahepatic lesions of hepatocellular carcinoma (HCC) have been controlled by significant advances in treatment including chemotherapy, surgery, and ablative therapy. Consequently, the number of patients with extrahepatic metastatic lesions has increased including lung, regional lymph nodes, peritoneum and adrenal glands, but rarely to brain. The prognosis of brain metastasis remains poor with approximately <1 y of survival from the time of diagnosis. Although no guidelines for the brain metastasis of HCC have been developed to date due to the lack of the experiences and evidences, a molecularly targeted drug, sorafenib, have been used to treat extrahepatic lesions and shown the prolonged survival time. Therefore, the development of standard therapy for brain metastasis following the early diagnosis is essential by accumulating the information of clinical courses and evidences. https://acta.tums.ac.ir/index.php/acta/article/view/7998 https://acta.tums.ac.ir/index.php/acta/article/download/7998/5367